An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-Dose Interferon on Progression-Free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2015
At a glance
- Drugs Bevacizumab (Primary) ; Interferon alpha-2a
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Roche
- 26 May 2015 Primary and secondary endpoints are amended.
- 14 Jan 2013 Planned end date changed from 1 Nov 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.